Zydus Lifesciences Limited, an innovation-led global life-sciences company, and Torrent Pharmaceuticals Limited, a specialty-focused global pharmaceutical company, have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market.
Job Overview
Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name SEMBOLICTM. Zydus will market the product under its brand names SEMAGLYNTM, MASHEMATM, and ALTERMETM. Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device.
Conclusion
This partnership brings together Zydus’s strong product development and manufacturing capabilities and Torrent Pharma’s deep market expertise across India, with the shared objective of improving patient access to advanced GLP-1 therapies for metabolic disorders.
